مباشر
Clinical OMICsPioneering Innovation in Transplant DiagnosticsFierceBiotechRoche nabs EU approval on label expansions for companion dx platformFierceBiotechGenentech executes another round of layoffs, with 3 VPs axedScienceLaser-boosted microscopes could reveal new drug targets, sharpen views inside cellsScienceThe ocean current that warms Europe may be more resilient than fearedClinical OMICsCyclana Bio Is Exploring the Extracellular Matrix to Treat EndometriosisFierceBiotechAI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data findsClinical OMICsHigher Vitamin C Levels in Blood Linked to Healthier Aging BrainsClinical OMICsStopping Neurodegeneration in Place with VaccinesClinical OMICsRemote Monitoring Benefits Unclear After Hospitalization for Serious InfectionFierceBiotechNovo reports data breach, tells clinical trial patients to 'remain vigilant'Endpoints NewsThe seeming inevitability of rising healthcare costs
BioWorld ٢٢ يناير ٢٠٢٦

Corcept’s relacorilant could reach $2.1B ovarian cancer market

Corcept’s relacorilant could reach $2.1B ovarian cancer market

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.